China NT Pharma Group Company Limited (HKG:1011)
Hong Kong · Delayed Price · Currency is HKD 0.7500
0.00 (0.00%)
At close: Feb 13, 2026
HKG:1011 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 18.66 | 37.96 | 7.37 | - | 226.7 | 221.73 | |
Revenue Growth (YoY) | -3.48% | 415.34% | - | - | 2.24% | 44.48% |
Cost of Revenue | 9.09 | 32.7 | - | - | 81.24 | 86.83 |
Gross Profit | 9.57 | 5.26 | 7.37 | - | 145.46 | 134.9 |
Selling, General & Admin | 21.5 | 18.49 | 63.57 | 22.62 | 229.19 | 219.33 |
Other Operating Expenses | - | - | - | - | - | -10.01 |
Operating Expenses | 21.5 | 18.49 | 63.57 | 26.54 | 238.93 | 207.93 |
Operating Income | -11.93 | -13.23 | -56.21 | -26.54 | -93.47 | -73.03 |
Interest Expense | -40.14 | -31.54 | -28.82 | -39.37 | -88.73 | -85.11 |
Interest & Investment Income | 0.01 | 0.01 | 0.01 | 0.04 | 0.24 | 2.84 |
Earnings From Equity Investments | 2.35 | 10.24 | 37.04 | 9 | 34.49 | 0.01 |
Currency Exchange Gain (Loss) | - | - | - | - | 6.66 | 16.13 |
Other Non Operating Income (Expenses) | -6.35 | -6.06 | 0.26 | 0.5 | 6.5 | -70.13 |
EBT Excluding Unusual Items | -56.05 | -40.58 | -47.71 | -56.37 | -134.32 | -209.3 |
Merger & Restructuring Charges | - | - | - | - | -1.4 | - |
Gain (Loss) on Sale of Investments | -8.14 | -5.92 | - | -0.63 | -6.04 | - |
Gain (Loss) on Sale of Assets | -7.01 | -7.01 | 12.29 | - | 41.04 | 0.3 |
Asset Writedown | - | - | - | - | - | 10.98 |
Legal Settlements | - | - | - | - | -40.63 | -2.27 |
Other Unusual Items | 0.03 | 0.03 | 2.05 | 6.95 | -7.4 | - |
Pretax Income | -71.17 | -53.48 | -33.37 | -50.04 | -148.75 | -200.29 |
Income Tax Expense | -0.25 | -0.12 | 0.12 | - | 2.58 | -9.02 |
Earnings From Continuing Operations | -70.92 | -53.36 | -33.49 | -50.04 | -151.33 | -191.27 |
Earnings From Discontinued Operations | - | - | -110.1 | -16.37 | - | -168.64 |
Net Income to Company | -70.92 | -53.36 | -143.59 | -66.41 | -151.33 | -359.91 |
Minority Interest in Earnings | - | - | - | - | 1.8 | 2.31 |
Net Income | -70.92 | -53.36 | -143.59 | -66.41 | -149.54 | -357.6 |
Net Income to Common | -70.92 | -53.36 | -143.59 | -66.41 | -149.54 | -357.6 |
Shares Outstanding (Basic) | 411 | 264 | 239 | 190 | 189 | 189 |
Shares Outstanding (Diluted) | 411 | 264 | 239 | 190 | 189 | 189 |
Shares Change (YoY) | 65.59% | 10.72% | 25.59% | 0.51% | 0.14% | 6.98% |
EPS (Basic) | -0.17 | -0.20 | -0.60 | -0.35 | -0.79 | -1.90 |
EPS (Diluted) | -0.17 | -0.20 | -0.60 | -0.35 | -0.79 | -1.90 |
Free Cash Flow | -22.74 | -9.24 | 39.74 | 31.72 | -135.98 | 2.36 |
Free Cash Flow Per Share | -0.06 | -0.04 | 0.17 | 0.17 | -0.72 | 0.01 |
Gross Margin | 51.27% | 13.86% | 100.00% | - | 64.16% | 60.84% |
Operating Margin | -63.93% | -34.84% | -763.07% | - | -41.23% | -32.93% |
Profit Margin | -380.13% | -140.56% | -1949.36% | - | -65.96% | -161.28% |
Free Cash Flow Margin | -121.87% | -24.35% | 539.55% | - | -59.98% | 1.06% |
EBITDA | -11.88 | -13.18 | -51.63 | -9.39 | -57.27 | -52.76 |
EBITDA Margin | -63.67% | -34.72% | - | - | -25.26% | -23.79% |
D&A For EBITDA | 0.05 | 0.05 | 4.58 | 17.16 | 36.2 | 20.27 |
EBIT | -11.93 | -13.23 | -56.21 | -26.54 | -93.47 | -73.03 |
EBIT Margin | -63.93% | -34.84% | - | - | -41.23% | -32.93% |
Advertising Expenses | - | - | - | - | 141.48 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.